Arterial hypertension has been recognized as a major causal factor for atrial fibrillation (AF), the most common sustained cardiac arrhythmia. In light of its worldwide increasing prevalence and incidence and the accompanied increase in the risk of stroke, thromboembolic events and mortality, AF has emerged as a global healthcare problem.
Early diagnosis of AF, prior to the occurrence of complications is a recognized priority for the prevention of strokes. Once diagnosed, anticoagulant therapy is the cornerstone in the management of the risk of stroke in AF patients. The 2012 ESC Guidelines recommend the use of a risk factor-based approach to stroke risk stratification for AF patients.
This study aims towards gaining real-world data on the prevalence of non-valvular atrial fibrillation (NVAF) among hypertensives in Greece. The rate of ESC guideline-adherent antithrombotic therapy on the basis of stroke and bleeding risk assessments, and factors influencing treatment decision-making will be assessed as well in patients diagnosed with the arrhythmia.
Finally, potential differences in the NVAF prevalence in adequately and inadequately controlled hypertensives will be documented.
- Standard of care Drug
Intervention Desc: As prescribed by treated physician ARM 1: Kind: Experimental Label: Cohort 1 Description: Patients aged 60 years or older regardless of gender and race with a documented diagnosis of hypertension will be enrolled into this study after the decision for electrocardiographic screening for AF has been made by the investigator
- Observation: Case-Only
- Perspective: Cross-Sectional
- Sampling: Probability Sample
The study will be carried out by hypertension specialists practicing in the hospital-based outpatient healthcare sector, among the network of the European Society of Hypertension (ESH) Hypertension Excellence Centers
|Type||Measure||Time Frame||Safety Issue|
|Primary||Frequency of non-valvular atrial fibrillation (NAVF) among hypertensive outpatients||At enrollment||No|
|Secondary||Proportion of NVAF patients for whom the HAS-BLED score has been estimated by the physicians as part of the decision for antithrombotic treatment||At enrollment||No|
|Secondary||Frequency of oral anticoagulation therapy among the study population diagnosed with NVAF||At enrollment||No|
|Secondary||Proportion of untreated patients among the study population diagnosed with NVAF||At enrollment||No|
|Secondary||Proportion of antiplatelet therapy treated patients among the study population diagnosed with NVAF||At enrollment||No|
|Secondary||CHADS2 scores||At enrollment||No|
|Secondary||CHA2DS2-VASc scores||At enrollment||No|
|Secondary||Degree of agreement between the proportions of patients classified at intermediate and high stroke risk according to the two risk stratification systems||At enrollment||No|
|Secondary||CHA2DS2-VASc score in hypertensives without NVAF||At enrollment||No|
|Secondary||Correlation of the CHA2DS2-VASc-assessed risk with the average annual stroke risk as calculated by the Framingham stroke risk scoring system in hypertensives without NVAF||At enrollment||No|
|Secondary||CHA2DS2-VASc score in hypertensives without AF||At enrollment||No|
|Secondary||Correlation of the CHA2DS2-VASc-assessed risk with the average annual AF risk as calculated by the Framingham AF risk scoring system in hypertensives without AF||At enrollment||No|
|Secondary||Frequency of NVAF among the subpopulations of hypertensives adequately versus those inadequately controlled according to the physicians' medical judgement||At enrollment||No|
- Bayer Lead